SRY Labs
Finnrick has tested 121 samples from SRY Labs across 11 products.
Take Action
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| Semaglutide | 4 | 29 Jun 2025 | 15 Jan 2026 | |||||
| Cagrilintide | 8 | 20 Apr 2025 | 8 May 2026 | |||||
| Sermorelin | 3 | 20 Apr 2025 | 6 Mar 2026 | |||||
| Tirzepatide | 35 | 15 May 2025 | 6 May 2026 | |||||
| BPC-157 | 7 | 17 May 2025 | 6 Nov 2025 | |||||
| CJC-1295 | 4 | 10 Jun 2025 | 21 Aug 2025 | |||||
| GHK-Cu | 7 | 10 Sep 2025 | 2 Feb 2026 | |||||
| PT-141 | 2 | 26 Jun 2025 | 29 Jun 2025 | |||||
| Retatrutide | 31 | 20 Apr 2025 | 8 Jun 2026 | |||||
| TB-500 | 8 | 16 May 2025 | 30 Jan 2026 | |||||
| Tesamorelin | 12 | 27 Jun 2025 | 2 Mar 2026 | |||||
The SRY Labs samples tested by Finnrick were either acquired by Finnrick directly, or submitted by the public.
Customer Reviews
These indicators of customer satisfaction are based on reports submitted by the public through the Finnrick testing program, and are not verified.
Based on 12 overall satisfaction reports
People who submitted test requests to Finnrick gave SRY Labs an average satisfaction rating of 4.8 out of 5 across 12 reports associated with samples received and tested by Finnrick. Customers rated payment methods (4.4/5) comparatively lower.
Most recent SRY Labs tests
Samples are tested in commercial labs
tests
products
Scores
First
Last
| Quantity | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Test Score | Label | Batch | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 8 Jun 2026 | Retatrutide | View | 30mg | 34.5mg | 33.2mg | -3.8% | 99.80% | F21750628 | No label / Silver crimp / Black cap | Lab G | Public | |
| 8 May 2026 | Cagrilintide | View | 10mg | (no batch claim) | 12.6mg | +26.0% | 99.60% | (no batch ID) | White Label / Silver Crimp / Green Cap | Lab G | Public | |
| 6 May 2026 | Tirzepatide | View | 20mg | (no batch claim) | 23.8mg | +19.0% | 99.90% | G23050728 | No Label / Silver Crimp / Clear Cap | Lab E | Public | |
| 23 Apr 2026 | Tirzepatide | View | 100mg | (no batch claim) | 101mg | +1.0% | 99.90% | November 2026 | No Label / Black Crimp / Clear Cap | Lab E | Public | |
| 25 Mar 2026 | Retatrutide | View | 10mg | (no batch claim) | 11.3mg | +13.0% | 99.70% | (no batch ID) | No Label / Silver Crimp / White Cap | Lab G | Public | |
| 25 Mar 2026 | Tirzepatide | View | 10mg | (no batch claim) | 10.3mg | +3.0% | 99.70% | (no batch ID) | No Label / Silver Crimp / Green Cap | Lab G | Public | |
| 19 Mar 2026 | Retatrutide | View | 5mg | (no batch claim) | 4.2mg | -16.0% | 99.90% | (no batch ID) | White Label / Silver Crimp / Clear Cap | Lab E | Public | |
About SRY Labs Test Results From Finnrick
SRY Labs is a peptide vendor with multiple products tracked in the independent testing dataset collected by Finnrick. This page compiles recent, batch-level test results across 11 products and 121 tests, including scores, test dates, batch IDs, and lab details. This enables you to compare quality over time, not just marketing claims.
Each tested sample receives a 0–10 score, with 10 being the best possible value. It is the total of three components: purity (0–4 points), quantity accuracy vs. the label or batch claim (0–4 points), and batch information quality (0–2 points).
When several test results are available for a product and vendor pair, you’ll also find a Finnrick Rating (A–E, where A is best and E is worst, X if an insufficient number of tests is available, or F in rare cases of documented and widespread fraud) and customer satisfaction reports with sub-scores that provide additional context. Use the table above to review purity, quantity accuracy, consistency between batches, and any notable outliers surfaced in Finnrick testing data.
SRY Labs Testing Activity & Score Summary
In the past 30 days, Finnrick has published no new test results for SRY Labs, and 4 in the past three months. The overall dataset includes 121 tested samples with an average score of 6.4/10 across all products.
Across 121 identity-tested samples, 98% were confirmed to contain the expected peptide (identity pass rate). Among those that passed, median purity was 99.8%. Approximately 89% of passing samples tested at or above 98% purity.
Here is a closer look at the most frequently tested products (top 3):
- Tirzepatide (35 tests, 100% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 3.4 to 10.0 (average 7.8/10), suggesting significant batch-to-batch differences.
- Retatrutide (31 tests, 97% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 1.5 to 10.0 (average 7.4/10), suggesting significant batch-to-batch differences.
- Cagrilintide (8 tests, 100% identity pass, median purity 99.5%) — Test scores are highly variable, ranging from 3.5 to 9.0 (average 5.8/10), suggesting significant batch-to-batch differences.